CTI BioPharma), still under a clinical hold enforced by the FDA back in February for its investigational JAK2 inhibitor candidate pacritinib, has posted new…

Ferring Pharmaceuticals has secured the rights to a Phase III treatment of radicular leg pain outside of Japan from Seikagaku.

TG Therapeutics got orphan drug designation from the FDA for both its clinical candidates this week.

Sofinnova Ventures, which over the course of its now ten funds has evolved its focus from early-stage life science and tech firms to later stage biotechs, has…

Belgium biotech argenx has seen its income double on the back of a strong year of deals, but has also seen fit to cut two former R&D pacts.

Struggling microcap GenVec has again been warned that it will be taken off the lucrative and respected Nasdaq exchange if it doesn’t get itself out of the…

Adocia has cut loose its diabetic foot ulcer program after the drug failed a Phase III trial.

Novartis has hit the primary endpoint in what it says is the largest randomized, controlled study to date to treat secondary progressive multiple sclerosis…